Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study

Authors

  • Cathrine F. Hjorth Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
  • Anja S. Nielsen Department of Pathology, Aarhus University Hospital, Aarhus, Denmark
  • Henrik T. Sørensen Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
  • Timothy L. Lash Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;   Department of Epidemiology, Rollins School of Public Health, and Winship Cancer Institute, Emory University, Atlanta, USA
  • Per Damkier Institute of Clinical Research, University of Southern Denmark, Odense, Denmark;   Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
  • Stephen Hamilton-Dutoit Department of Pathology, Aarhus University Hospital, Aarhus, Denmark
  • Deirdre Cronin-Fenton Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

DOI:

https://doi.org/10.1080/0284186X.2018.1537508

Abstract

Background: Adjuvant tamoxifen therapy approximately halves the risk of recurrence in estrogen receptor-positive (ER+) breast cancer patients, but many women respond insufficiently to therapy. Expression of multi-drug resistance protein 2 (MRP2) in breast cancer may potentiate tamoxifen resistance. Thus, we investigated the expression of MRP2 in breast cancer as a predictor of tamoxifen therapy effectiveness.

Material and methods: We conducted a case-control study nested in the Danish Breast Cancer Group clinical database. The study included women aged 35–69 years diagnosed with stage l–lll breast cancer during 1985–2001, in Jutland, Denmark. We identified 541 recurrent breast cancers (cases) among women with estrogen receptor positive (ER+) disease treated with tamoxifen for at least 1 year (ER+/TAM+) and 300 cases among women with estrogen receptor-negative (ER−) disease, never treated with tamoxifen (ER−/TAM−). We matched one recurrence-free control to each recurrent case. We retrieved paraffin-embedded primary tumor tissue for all patients, and all available recurrent tumor tissue from pathology archives. MRP2 expression was evaluated using immunohistochemistry. We computed odds ratios (ORs) and 95% confidence intervals (95% CIs) associating MRP2 expression (positive vs. none) with breast cancer recurrence in conditional logistic regression models. We compared MRP2 expression in paired primary- and recurrent tumors.

Results: MRP2 expression was more prevalent in the ER+/TAM + group, than in the ER−/TAM − group. No predictive utility of MRP2 for breast cancer recurrence was found in the ER+/TAM + group (ORadj = 0.96, 95% CI 0.70, 1.33). Further, no prognostic utility was found in the ER−/TAM − group (ORadj = 0.81, 95% CI 0.53, 1.23). MRP2 expression was not increased in recurrent versus primary tumors.

Conclusions: MRP2 expression is neither a predictive marker of tamoxifen effectiveness nor a prognostic marker in breast cancer.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2019-02-01

How to Cite

Hjorth, C. F., Nielsen, A. S., Sørensen, H. T., Lash, T. L., Damkier, P., Hamilton-Dutoit, S., & Cronin-Fenton, D. (2019). Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. Acta Oncologica, 58(2), 168–174. https://doi.org/10.1080/0284186X.2018.1537508

Issue

Vol. 58 No. 2 (2019): Acta Oncologica

Section

Articles